| Scrip Code | 531349 |
|---|---|
| NSE Symbol | PANACEABIO |
| MSEI Symbol | NOTLISTED |
| ISIN | INE922B01023 |
| Name of company | Panacea Biotec Limited |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2026 |
| Date of end of financial year | 31-03-2027 |
| Date of board meeting when results were approved | 13-08-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 08-08-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | First quarter |
| Nature of report standalone or consolidated | Consolidated |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | |
| Segment Reporting | Multi segment |
| Description of single segment | |
| Start date and time of board meeting | 13-08-2026 16:46:00 |
| End date and time of board meeting | 13-08-2026 17:27:00 |
| Whether cash flow statement is applicable on company | |
| Type of cash flow statement | |
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| 1 | Income | ||
| Revenue from operations | 19,957.00 | 19,957.00 | |
| Other income | 424.00 | 424.00 | |
| Total income | 20,381.00 | 20,381.00 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 7,417.00 | 7,417.00 |
| (b) | Purchases of stock-in-trade | 77.00 | 77.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | 2,677.00 | 2,677.00 |
| (d) | Employee benefit expense | 4,416.00 | 4,416.00 |
| (e) | Finance costs | 118.00 | 118.00 |
| (f) | Depreciation, depletion and amortisation expense | 790.00 | 790.00 |
| (f) | Other Expenses | ||
| 1 | Other Expenses | 4,803.00 | 4,803.00 |
| Total other expenses | 4,803.00 | 4,803.00 | |
| Total expenses | 20,298.00 | 20,298.00 | |
| 3 | Total profit before exceptional items and tax | 83.00 | 83.00 |
| 4 | Exceptional items | 274.00 | 274.00 |
| 5 | Total profit before tax | 357.00 | 357.00 |
| 6 | Tax expense | ||
| 7 | Current tax | 39.00 | 39.00 |
| 8 | Deferred tax | 98.00 | 98.00 |
| 9 | Total tax expenses | 137.00 | 137.00 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 220.00 | 220.00 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | 220.00 | 220.00 |
| 17 | Other comprehensive income net of taxes | 38.00 | 38.00 |
| 18 | Total Comprehensive Income for the period | 258.00 | 258.00 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | 230.00 | 230.00 | |
| Total profit or loss, attributable to non-controlling interests | (10.00) | (10.00) | |
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | 268.00 | 268.00 | |
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | (10.00) | (10.00) | |
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 613.00 | 613.00 | |
| Face value of equity share capital | 1 | 1 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 0.38 | 0.38 | |
| Diluted earnings (loss) per share from continuing operations | 0.38 | 0.38 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 0.38 | 0.38 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 0.38 | 0.38 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | Notes: 1. The financial results for the quarter ended June 30, 2026 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 13, 2026, and have been reviewed by the statutory auditor of the Company. 2. The financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (“Ind AS”) notified under the Companies (Indian Accounting Standards) Rule, 2015, as amended from time to time, specified under section 133 of the Companies Act, 2013. 3. The consolidated financial results of the Company have been prepared by consolidating the unaudited financial results of the Company and its material subsidiary Panacea Biotec Pharma Limited (“PBPL”) for the respective periods, with the unaudited (management reviewed and approved) financial results of its wholly owned subsidiaries (“WOS”) and the enterprises over which the Company exercises control (“Enterprises”) (the Company, these subsidiaries and the Enterprises hereinafter collectively referred to as “the Group”) for the respective periods: (i) WOS: Meyten Realtech Private Limited, Panacea Biotec (International) S.A. (“PBS”), Panacea Biotec Germany GmbH (WOS through PBS) and Panacea Biotec Inc. (WOS through PBPL); and (ii) Enterprises: PanEra Biotec Private Limited and Adveta Power Private Limited. considered as a subsidiary for the purpose of consolidation as per Ind AS 110 4. For the quarter ended June 30, 2026, the Company and Group has earned profit (including other comprehensive income) of Rs.167 lakh and Rs.258 lakh (quarter ended June 30, 2025: loss of Rs.668 lakh and profit of Rs.394 lakh), respectively. As on June 30, 2026, the retained earnings of the Company are negative to the extent of Rs.21,615 lakh (June 30, 2025: Rs.19,577 lakh). The aforesaid conditions indicate the existence of uncertainty that may create doubt about the Company's ability to continue as a going concern. However, the retained earnings of the Group as on June 30, 2026 are positive. The surplus funds remaining with the Group out of the sales of pharmaceutical formulations brands in India and Nepal in March 2022 have helped in strengthening the working capital position, setting up new facilities for enhancement of capacities for manufacturing of vaccines drug substance, scaling up its nutrition and pharmaceutical formulations business and pursuing other business opportunities. The Company has already received higher long-term business orders for vaccines from key institutional customers, resulting into higher revenues and profits during the current quarter. Based on these measures and continuous efforts to improve the business performance, the management has prepared the financial results on a going concern basis. |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-04-2026 | 01-04-2026 | |||||
| Date of end of reporting period | 30-06-2026 | 30-06-2026 | |||||
| Whether results are audited or unaudited | Unaudited | Unaudited | |||||
| Nature of report standalone or consolidated | Consolidated | Consolidated | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| 1 | Vaccines | 13,467.00 | 13,467.00 | ||||
| 2 | Formulations | 6,490.00 | 6,490.00 | ||||
| Total Segment Revenue | 19,957.00 | 19,957.00 | |||||
| Less: Inter segment revenue | 0.00 | 0.00 | |||||
| Revenue from operations | 19,957.00 | 19,957.00 | |||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| 1 | Vaccines | 747.00 | 747.00 | ||||
| 2 | Formulations | (390.00) | (390.00) | ||||
| Total Profit before tax | 357.00 | 357.00 | |||||
| i. Finance cost | 0.00 | 0.00 | |||||
| ii. Other Unallocable Expenditure net off Unallocable income | 0.00 | 0.00 | |||||
| Profit before tax | 357.00 | 357.00 | |||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| 1 | Vaccines | 91,203.00 | 91,203.00 | ||||
| 2 | Formulations | 38,245.00 | 38,245.00 | ||||
| Total Segment Asset | 1,29,448.00 | 1,29,448.00 | |||||
| Un-allocable Assets | 0.00 | 0.00 | |||||
| Net Segment Asset | 1,29,448.00 | 1,29,448.00 | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| 1 | Vaccines | 33,164.00 | 33,164.00 | ||||
| 2 | Formulations | 13,151.00 | 13,151.00 | ||||
| Total Segment Liabilities | 46,315.00 | 46,315.00 | |||||
| Un-allocable Liabilities | 0.00 | 0.00 | |||||
| Net Segment Liabilities | 46,315.00 | 46,315.00 | |||||
| Disclosure of notes on segments | Textual Information(2) | ||||||
| Textual Information(2) | 5. During the quarter ended June 30, 2026, the Group has recognised exceptional income of Rs.274 lakh (quarter ended June 30, 2025: Rs.1,132 lakh) in the consolidated statement of profit and loss, which includes: (i) income of Rs. Nil (quarter ended June 30, 2025: Rs.858 lakh), pursuant to the settlement agreement dated July 9, 2025 executed with Apotex Inc., USA (“Apotex”) to settle the ongoing dispute between Apotex and the Company & PBPL; and (ii) income of Rs.274 Lakh (quarter ended June 30, 2025: Rs.274 lakh), out of the remaining deferred consideration of Rs.1,019 Lakh as at March 31, 2026, from sale of domestic pharmaceutical brands of PBPL. The balance deferred consideration of Rs.745 lakh (June 30, 2025: Rs.1,837 lakh) would be recognised in subsequent quarters / years and is shown as Contract Liability in the consolidated financial statements of the Group. 6. Amounts for the quarter ended March 31, 2026 represent the balancing amounts between the audited amounts for the full financial year and the published year to date amounts upto third quarter of the financial year ended March 31, 2026, which had been subjected only to limited review. 7. The Company publishes standalone financial results along with the consolidated financial results. In accordance with Ind AS 108, ‘Operating Segments’, the management has disclosed the segment information in the consolidated financial results. Accordingly, the segment information is given in the consolidated financial results of the Group for the quarter ended June 30, 2026. 8. The necessary certificate / report in respect of the above results in terms of requirements of Regulation 33 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 2015, has been placed before the Board of Directors. 9. Previous period amounts have been regrouped/ reclassified in compliance with Ind-AS to make them comparable with those of current period / year. 10. ‘0’ under “Rs. in Lakh” represents an amount less than Rs.50,000. Further, the figures shown in the tables may not exactly add up due to rounding off. 11. The above results are also available on the Company’s website https://www.panaceabiotec.com. |
|---|
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Items that will not be reclassified | 51.00 | 51.00 |
| Total Amount of items that will not be reclassified to profit and loss | 51.00 | ||
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 13.00 | 13.00 |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| 1 | Items that will be reclassified | 0.00 | 0.00 |
| Total Amount of items that will be reclassified to profit and loss | 0.00 | ||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0.00 | 0.00 |
| 5 | Total Other comprehensive income | 38.00 | 38.00 |